Founded in 2002, Aurigene has now progressed into a clinical stage biotech company committed to bringing novel therapeutics for the treatment of cancer.
Over the past two decades, Aurigene has:
built comprehensive Drug Discovery & Development capabilities,
worked on over 80 integrated Drug Discovery projects,
contributed to delivering over 17 small molecule and peptide drug candidates, currently in global clinical development.
Aurigene has out-licensed several first-in-class and best-in-class compounds to pharma and biotech companies for global clinical development, while undertaking clinical development of a few programs on its own.
Aurigene has developed deep expertise in cancer, and has continuously invested in its people resources and infrastructure over the years